Test TL-895 plus ruxolitinib for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can give informed consent
- You have a confirmed diagnosis of primary myelofibrosis or post–polycythemia vera/essential thrombocythemia myelofibrosis
- If you are already on ruxolitinib, your dose must be stable before starting the study
- Your risk level must be one of the study’s higher-risk groups (DIPSS low enough to include intermediate/high risk)
- You have an enlarged spleen (either measured by scan/volume or felt as at least 5 cm below a chest landmark)
- Your strength/mobility is good enough for study participation (ECOG 0 to 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.